Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.

Figueiredo TH, Qashu F, Apland JP, Aroniadou-Anderjaska V, Souza AP, Braga MF.

J Pharmacol Exp Ther. 2011 Feb;336(2):303-12. doi: 10.1124/jpet.110.171835. Epub 2010 Oct 20.

PMID:
20962029
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.

Apland JP, Aroniadou-Anderjaska V, Figueiredo TH, Green CE, Swezey R, Yang C, Qashu F, Braga MF.

J Pharmacol Exp Ther. 2013 Jan;344(1):133-40. doi: 10.1124/jpet.112.198689. Epub 2012 Oct 5.

PMID:
23042954
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisoquinoline- 3-carboxylic acid (LY293558) and its racemate (LY215490).

Schoepp DD, Salhoff CR, Fuson KS, Sacaan AI, Tizzano JP, Ornstein PL, May PC.

J Neural Transm. 1996;103(8-9):905-16.

PMID:
9013384
[PubMed - indexed for MEDLINE]
4.

In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.

Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, Bleakman D, Witkin JM.

Psychopharmacology (Berl). 2006 Apr;185(2):240-7. Epub 2006 Feb 10.

PMID:
16470401
[PubMed - indexed for MEDLINE]
5.

Soman induces ictogenesis in the amygdala and interictal activity in the hippocampus that are blocked by a GluR5 kainate receptor antagonist in vitro.

Apland JP, Aroniadou-Anderjaska V, Braga MF.

Neuroscience. 2009 Mar 3;159(1):380-9. doi: 10.1016/j.neuroscience.2008.11.053. Epub 2008 Dec 14.

PMID:
19136046
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The limitations of diazepam as a treatment for nerve agent-induced seizures and neuropathology in rats: comparison with UBP302.

Apland JP, Aroniadou-Anderjaska V, Figueiredo TH, Rossetti F, Miller SL, Braga MF.

J Pharmacol Exp Ther. 2014 Nov;351(2):359-72. doi: 10.1124/jpet.114.217299. Epub 2014 Aug 25.

PMID:
25157087
[PubMed - indexed for MEDLINE]
7.

Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons.

Braga MF, Aroniadou-Anderjaska V, Li H, Rogawski MA.

J Pharmacol Exp Ther. 2009 Aug;330(2):558-66. doi: 10.1124/jpet.109.153908. Epub 2009 May 5.

PMID:
19417176
[PubMed - indexed for MEDLINE]
Free Article
8.

Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse.

Rogawski MA, Kurzman PS, Yamaguchi SI, Li H.

Neuropharmacology. 2001;40(1):28-35.

PMID:
11077068
[PubMed - indexed for MEDLINE]
9.

Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid.

Bleakman R, Schoepp DD, Ballyk B, Bufton H, Sharpe EF, Thomas K, Ornstein PL, Kamboj RK.

Mol Pharmacol. 1996 Apr;49(4):581-5.

PMID:
8609884
[PubMed - indexed for MEDLINE]
10.

Neuroprotective efficacy of caramiphen against soman and mechanisms of its action.

Figueiredo TH, Aroniadou-Anderjaska V, Qashu F, Apland JP, Pidoplichko V, Stevens D, Ferrara TM, Braga MF.

Br J Pharmacol. 2011 Nov;164(5):1495-505. doi: 10.1111/j.1476-5381.2011.01427.x.

PMID:
21486285
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

LY293558 prevents soman-induced pathophysiological alterations in the basolateral amygdala and the development of anxiety.

Prager EM, Figueiredo TH, Long RP 2nd, Aroniadou-Anderjaska V, Apland JP, Braga MF.

Neuropharmacology. 2015 Feb;89:11-8. doi: 10.1016/j.neuropharm.2014.08.014. Epub 2014 Sep 6.

PMID:
25204221
[PubMed - in process]
12.

In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid.

Schoepp DD, Lodge D, Bleakman D, Leander JD, Tizzano JP, Wright RA, Palmer AJ, Salhoff CR, Ornstein PL.

Neuropharmacology. 1995 Sep;34(9):1159-68.

PMID:
8532186
[PubMed - indexed for MEDLINE]
13.

Combined diazepam and HDAC inhibitor treatment protects against seizures and neuronal damage caused by soman exposure.

Rossetti F, de Araujo Furtado M, Pak T, Bailey K, Shields M, Chanda S, Addis M, Robertson BD, Moffett M, Lumley LA, Yourick DL.

Neurotoxicology. 2012 Jun;33(3):500-11. doi: 10.1016/j.neuro.2012.02.010. Epub 2012 Feb 24.

PMID:
22387230
[PubMed - indexed for MEDLINE]
14.

Exposure to nerve agents: from status epilepticus to neuroinflammation, brain damage, neurogenesis and epilepsy.

de Araujo Furtado M, Rossetti F, Chanda S, Yourick D.

Neurotoxicology. 2012 Dec;33(6):1476-90. doi: 10.1016/j.neuro.2012.09.001. Epub 2012 Sep 7. Review.

PMID:
23000013
[PubMed - indexed for MEDLINE]
15.

LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.

Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, Silberstein SD, Johnson KW, Phebus LA, Bleakman D, Ornstein PL, Arnold B, Tepper SJ, Vandenhende F.

Cephalalgia. 2004 Jul;24(7):596-602.

PMID:
15196302
[PubMed - indexed for MEDLINE]
16.

Acetylcholinesterase inhibition in the basolateral amygdala plays a key role in the induction of status epilepticus after soman exposure.

Prager EM, Aroniadou-Anderjaska V, Almeida-Suhett CP, Figueiredo TH, Apland JP, Braga MF.

Neurotoxicology. 2013 Sep;38:84-90. doi: 10.1016/j.neuro.2013.06.006. Epub 2013 Jun 29.

PMID:
23817175
[PubMed - indexed for MEDLINE]
17.

The recovery of acetylcholinesterase activity and the progression of neuropathological and pathophysiological alterations in the rat basolateral amygdala after soman-induced status epilepticus: relation to anxiety-like behavior.

Prager EM, Aroniadou-Anderjaska V, Almeida-Suhett CP, Figueiredo TH, Apland JP, Rossetti F, Olsen CH, Braga MF.

Neuropharmacology. 2014 Jun;81:64-74. doi: 10.1016/j.neuropharm.2014.01.035. Epub 2014 Jan 31.

PMID:
24486384
[PubMed - indexed for MEDLINE]
18.
19.

Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.

Weiss B, Alt A, Ogden AM, Gates M, Dieckman DK, Clemens-Smith A, Ho KH, Jarvie K, Rizkalla G, Wright RA, Calligaro DO, Schoepp D, Mattiuz EL, Stratford RE, Johnson B, Salhoff C, Katofiasc M, Phebus LA, Schenck K, Cohen M, Filla SA, Ornstein PL, Johnson KW, Bleakman D.

J Pharmacol Exp Ther. 2006 Aug;318(2):772-81. Epub 2006 May 11.

PMID:
16690725
[PubMed - indexed for MEDLINE]
Free Article
20.

Pathological alterations in GABAergic interneurons and reduced tonic inhibition in the basolateral amygdala during epileptogenesis.

Fritsch B, Qashu F, Figueiredo TH, Aroniadou-Anderjaska V, Rogawski MA, Braga MF.

Neuroscience. 2009 Sep 29;163(1):415-29. doi: 10.1016/j.neuroscience.2009.06.034. Epub 2009 Jun 18.

PMID:
19540312
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk